Prevalence and appropriateness of psychotropic medication prescribing in a nationally representative cross-sectional survey of male and female prisoners in England

Table 4 Proportion of prison prescriptions for psychotropic medications that met each PAI indicator by gender and BNF subchapter

PAI Indicator^a,		BNF Sub-chapter
		Hypnotics & anxiolytics		Antipsychotics & antimanics		Antidepressants		CNS Stimulants		Any Psychotropic
		%	n	%	n	%	n	%	n	%	n
Men
1	Valid indication^b	90.5	57	50.5	141	61.8	512	90.9	40	62.0	758
2	Generic product	100	64	97.5	273	100	832	100	44	99.4	1222
3	No drug-drug interaction	93.7	59	80.7	221	87.1	714	93.2	41	86.2	1043
4	Valid dose range	91.7	55	81.7	227	97.5	809	95.4	41	93.5	1132
Women
1	Valid indication^b	85.7	54	53.9	55	76.8	262	100	5	73.4	378
2	Generic product	98.5	66	99.1	104	100	343	100	5	99.6	522
3	No drug-drug interaction	100	59	69.0	69	84.4	286	100	5	83.4	423
4	Valid dose range	98.3	59	77.9	81	94.1	321	100	5	91.4	466
a Key
PAI Indicator
1	The indication for the drug is recorded and upheld in the BNF.
2	A generic product is prescribed, if one is available.
3	If a potentially hazardous drug-drug combination is prescribed, the prescriber shows knowledge of the hazard.
4	If the total daily dose is outside the range stated in the BNF or SPC, the prescriber gives a valid reason.
b Key
BNF sub-chapter	Valid indications (licensed and unlicensed), as listed in the BNF^a
Hypnotics & anxiolytics	Anxiety, insomnia, alcohol dependence, benzodiazepine dependence and allergies.
Antipsychotics and antimanics	Schizophrenia, psychosis, bipolar disorder, epilepsy, severe aggression or agitation.
Antidepressants	Depression, anxiety, bipolar disorder, obsessive compulsive disorder and post-traumatic stress disorder.
CNS Stimulants	Attention Deficit Hyperactivity Disorder

ISSN: 1471-244X